Trial
NCT02030574
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Brown University
Collaborators
Lifespan
Condition
Invasive Bladder Cancer
Intervention
Gemcitabine and fractionated cisplatin (combination treatment)
Why stopped
The study is being closed to accrual secondary to low accrual and an interest in opening up a different trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-08-24